logo
  

Genzyme Reveal Positive Results From Second Phase III Study Of Oral AUBAGIO

Genzyme, a Sanofi company (SNY) Friday announced positive results from the TOWER trial for Treatment and Research in Multiple Sclerosis.

TOWER is a Phase III, multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of AUBAGIO in patients with relapsing MS followed by an open-label extension period.

The company, engaged in the the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years, stzted thzt in the study, once-daily, oral AUBAGIO 14 mg significantly reduced the annualized relapse rate and slowed progression of disability in patients with relapsing forms of multiple sclerosis (MS) compared to placebo.

The company further added that the proportion of patients treated with AUBAGIO who were relapse-free was significantly higher compared to placebo.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The TJX Companies, Inc. (TJX) said its first-quarter pretax profit margin and earnings per share, each on an adjusted basis, exceeded its plans even though sales were slightly below planned range. Adjusted pretax margin was 9.4%, excluding a 1.9 percentage point charge related to a write-down of the... Apple Inc. is delaying its latest plan to ask employees to come back to the office three days a week, but will continue with its plan of two days in office a week, Bloomberg reported. Citing an internal memo, the report also said the tech major is again requiring its staff to wear masks in common spaces, meeting rooms, hallways, and elevators, as well as at 100 US stores. The U.S. Food and Drug Administration or FDA has urged infant formula manufacturers to import infant formula products to the United States to meet the ongoing severe supply shortage. In order to further increase the availability of infant formula in the country, while protecting the health of infants, the regulator announced a guidance outlining increased flexibilities for the global manufacturers
Follow RTT